Neurometers Request data room access
Platform Science Applications Opportunity Team Request data room access
Software Defined Neurology

Quantifying brain function
at scale, from EEG.

Neurometers turns everyday EEG into clinically validated biomarkers of brain function — starting with consciousness in the ICU. Fifteen years of research from the Paris Brain Institute, now deployed at the bedside.

Request data room access See the evidence

Spun out of the Paris Brain Institute · Used daily at Pitié-Salpêtrière neuro-ICU

Signal → Insight live at the bedside
Cz · 10 s
1,000+
patient EEG database
8–256
channels supported
TRL 6
used daily at Pitié-Salpêtrière
Vendor-agnostic
runs on the installed EEG base
Peer-reviewed in Nature MedicineNEJMBrainPNASClinical Neurophysiology
The problem

Neurology still can’t measure brain function at scale.

Molecular markers reflect pathology, not consciousness. Imaging is expensive and episodic. Behavioural tests need a cooperating patient. The result is uncertainty at exactly the moments that matter most — and it is expensive.

30–40%
diagnostic errors

of patients with disorders of consciousness are misclassified at the bedside — without quantified, repeatable measures of brain activity.

~6.2%
trial approval rate

for neurodegenerative-disease clinical trials — driven in large part by poor patient stratification and selection, which shrinks measured effect sizes.

$10B+
lost in failed CNS trials

in late-stage central-nervous-system trials over the last decade — capital erased for want of objective endpoints.

$5–10k
ICU cost per day

across 100k+ ICU beds in the US, where consciousness and prognosis decisions are made with incomplete information.

The platform

One signal infrastructure.
Many clinical outputs.

A SaaS layer on top of the EEG already installed in ~10,000 ICUs worldwide. We transform a low-margin imaging modality into a high-value, decision-driving asset — without adding staff or workflow friction.

01

EEG devices

Vendor-agnostic input, 8 to 256 channels — from ICU monitors to research high-density caps. No new hardware required.

→
02

Biomarker extraction

Automated extraction of spectral, complexity/entropy and connectivity biomarkers, plus validated cognitive protocols.

→
03

AI / ML core

Multivariate models trained on a proprietary 1,000+ patient EEG database — supervised, interpretable, indication-tunable.

→
04

Clinical outputs

Reliable, reproducible, actionable readouts of brain function — delivered in the cloud or on-site.

Trained on a proprietary database of 1,000+ patients, validated across centres, at TRL 6 — the first clinically deployed biomarker platform that measures consciousness directly from EEG.

Science & clinical evidence

Where scientific rigor becomes commercial potential.

Neurometers is not an AI claim in search of validation. Every layer of the platform traces back to landmark, peer-reviewed neuroscience — the same work that international guidelines now cite as standard of care. That foundation is the moat, and the map to each new market.

Brain Latest · 20262026 · 149(4): 1381–1395

Multimodal multicentre investigation of diagnostic and prognostic markers in disorders of consciousness

Manasova D., Belloli L.M.L., Rosenfelder M.J., … Muñoz-Musat E., … Rohaut B., Naccache L., Comanducci A., Arzi A., Rosanova M., Bender A., Sitt J.D.

Nearly 400 patients across France, Germany and Italy, assessed with resting and task-based EEG, structural, functional and diffusion MRI, and PET. Combining modalities significantly improves model performance: functional markers (EEG, PET) best capture the current state of consciousness, while structural markers best predict recovery — and discrepancies between EEG and imaging flag hidden awareness that bedside exams miss. The largest multicentre validation of the platform's markers to date, co-authored by Neurometers' CEO and scientific founders.

Multicentre validationRead the paper ↗
Brain · Neurobiol. Aging2019 · 2021

EEG evidence of compensatory mechanisms in preclinical Alzheimer’s disease & A machine learning approach to screen for preclinical Alzheimer’s disease

Gaubert S., Raimondo F., Houot M., et al. — Brain 142(7): 2096–2112 · Neurobiol. Aging 105: 205–216

The same EEG building blocks flagged neurodegeneration in cognitively normal adults from the INSIGHT-preAD cohort — with performance holding down to a 4-electrode setup. The bridge to Alzheimer’s.

Beyond consciousnessBrain 2019 ↗  ·  Neurobiol. Aging 2021 ↗
Clinical guideline

The European Academy of Neurology guideline recommends EEG-based assessment alongside the clinical exam for disorders of consciousness — noting that bedside evaluation alone can misclassify a large share of non-communicating patients.

Kondziella D., Bender A., Diserens K., et al. Eur. J. Neurol. 2020; 27(5): 741–756 · Read the guideline ↗
Expert consensus

An IFCN-endorsed expert group reviews quantitative-EEG and machine-learning classifiers as a scalable layer for the diagnostic and prognostic evaluation of disorders of consciousness — citing the Sitt (2014) and Engemann (2018) work at the core of the platform.

Comanducci A., Boly M., Claassen J., et al. Clin. Neurophysiol. 2020; 131(11): 2736–2765 · Read the review ↗
Applications

One validated core. A pipeline of indications.

Each new indication layers onto the same algorithmic core — expanding the market without multiplying R&D or deployment cost.

  1. Phase 1 · NowDeployed

    Disorders of consciousness

    Objective classification of coma, vegetative and minimally conscious states in the neuro- and general ICU. Deployed today at Pitié-Salpêtrière.

  2. Phase 2

    Alzheimer’s disease

    Screening and disease-progression monitoring from routine EEG — validated on preclinical cohorts down to a handful of electrodes.

  3. Phase 3

    Post-cardiac-arrest & ICU

    Recovery prediction after cardiac arrest and severe brain injury, layered onto the same validated algorithmic core.

  4. Later

    Anesthesia & stroke

    Real-time depth-of-anesthesia feedback and stroke recovery prediction — the platform’s long-tail of indications.

The opportunity

A large market, monetized through recurring software.

Neurometers sits at the intersection of brain monitoring, neuro-ICU care and CNS drug development — a market driven by ICU expansion, an aging population and pharma’s need for objective brain biomarkers.

TAM
~$7B

Global brain monitoring & neuro biomarkers

SAM
~$4B

ICU consciousness monitoring & neurodegeneration

SOM
~$400M

Initial serviceable footprint

A B2B model built to compound.

  • Monetizes the existing EEG install base — no new hardware to sell in
  • Recurring, high-margin software revenue (target 75–85% gross margin)
  • One validated core; new indications upsell without multiplying R&D
  • For pharma: better patient stratification means smaller trials and larger measured effect sizes

Hospitals & clinics

Installation, optional hardware lease, and tiered annual SaaS or per-assessment fees across neuro-ICU, general ICU, neuro-rehab and neurology clinics.

Pharma & medtech

Objective EEG biomarkers to stratify and select patients at enrolment — reducing the sample size needed and increasing the measured effect size of a drug — plus quantified endpoints for treatment monitoring. Per-study or per-enrolled-patient contracts, with success fees on approval.

Defensibility

Protected by IP, de-risked by a phased path to market.

Defensible IP

  • 5 patent families covering the core EEG biomarker technology
  • Exclusive license to existing & future patents from the Paris Brain Institute
  • 15+ years of peer-reviewed research and publications

Phased regulatory path

  • Software as a Medical Device — Class IIb
  • CE Mark (EU) targeted for the first indication, then FDA clearance (US)
  • De Novo pathway with anticipated Breakthrough Device Designation
Team

Built by the scientists who defined the field.

An operating team of clinician-scientists and engineers, anchored by the Paris Brain Institute researchers behind the foundational science.

Leadership

EMEsteban Muñoz Musat

Esteban Muñoz Musat

CEO · MD, PhD

Neurologist and cognitive neuroscientist, Pitié-Salpêtrière & Lariboisière hospitals. Medical Director of the Alois association.

NMNasr Makni

Nasr Makni

CTO · PhD

15+ years of experience in healthcare. PhD, University of Lille 1 · MSc, Centrale Lille.

LHLine Holtzer

Line Holtzer

Chief of Staff · MSc

ESPCI / Mines Paris engineer. Startup business manager at the Paris Brain Institute.

Co-founders

Five internationally recognised clinician-scientists, with over 20 years of research on consciousness.

LNLionel Naccache

Lionel Naccache

MD, PhD, Professor

Professor of Physiology, Sorbonne University · Head of Clinical Neurophysiology, Pitié-Salpêtrière · Paris Brain Institute.

JSJacobo Sitt

Jacobo Sitt

MD, PhD, Director of Research INSERM

Psychiatrist and physicist · Co-head, PICNIC Lab, Paris Brain Institute.

SDStanislas Dehaene

Stanislas Dehaene

PhD, Professor

Professor, Collège de France · Head of NeuroSpin (CEA).

BRBenjamin Rohaut

Benjamin Rohaut

MD, PhD, Professor

Professor of Neurology, Sorbonne University · Pitié-Salpêtrière.

FRFederico Raimondo

Federico Raimondo

PhD

Postdoctoral researcher, Forschungszentrum Jülich.

For investors

We’re raising our pre-seed to bring quantified neurology to the bedside.

Validated science, a deployed product, defensible IP and a clear regulatory path. Request access to the data room for the full picture — traction, roadmap, financials and terms.

Request data room access Back to top